Merck is discontinuing the phase 3 KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose combination of vibostolimab and pembrolizumab in certain patients with non-small cell lung ...
Zacks.com on MSN12h
Merck to End Development of Two Cancer Candidates: Time to Sell?We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...
US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an ...
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...
Merck (MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, announced that they have entered into an exclusive global license agreement ...
Leerink Partners analyst Daina Graybosch has maintained their bullish stance on MRK stock, giving a Buy rating on December 11.Pick the best ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback